Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective decreased by research analysts at Piper Sandler from $37.00 to $36.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s price objective would suggest a potential upside of 15.38% from the company’s current price.

Other equities analysts have also issued research reports about the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Trading Down 2.9 %

Shares of Collegium Pharmaceutical stock opened at $31.20 on Tuesday. The firm’s 50 day simple moving average is $31.02 and its two-hundred day simple moving average is $34.18. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 13.45 and a beta of 0.82. Collegium Pharmaceutical has a 12-month low of $28.39 and a 12-month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the period. TD Private Client Wealth LLC increased its position in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV increased its position in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.